Gedeon Richter has launched its biosimilar teriparatide, Terrosa® in Europe. The product is approved in adults for the same indications as Eli Lilly’s Forsteo®, i.e. used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated.

Biosimilar teriparatide has been developed by Richter-Helm BioTec GmbH & Co. KG. The product has been launched under the label Terrosa® by Richter via its affiliates in Europe immediately following the patent expiry of the reference product in August 2019.

The European Commission (EC) approved Terrosa® in January 2017, following the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP), which concluded that the data derived from the comprehensive physico-chemical and biological characterisation, in vivo non-clinical studies and the clinical trial, constituting the development programme of Terrosa® had demonstrated biosimilarity with Forsteo®. The EC approval of Terrosa® applies to all 28 European Union (EU) member states and European Economic Area (EEA) member states.

"We are excited about the introduction of Terrosa®, our first own-developed biosimilar product in Europe, as it reflects our commitment to scientific programmes linked to complex medications such as biologicals. Biosimilars will increase choice and access for patients in the European countries, while providing potential cost savings to healthcare systems. We look forward to bringing more high quality and affordable biosimilar products to the market", said Gábor Orbán, Chief Executive Officer of Richter.

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content, 

please email: Julia.Zhang@ubmsinoexpo.com to delete.